|
1. Biologie
|
|
|
|
|
|
2.11 Etiologie - Alimentation
|
|
|
|
|
3.4.1 Chimioprévention - aspirine
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
Califf: FDA can’t isolate itself from industry, despite ‘touchy’ issues [STAT]
|
|
|
|
|
|
He
noted, for example, that in “next-generation sequencing” — new
technologies that allow fast sequencing of a person’s DNA or entire
genome — the FDA is hiring people from industry and academia who have
the expertise to handle the science. “Six months after they are on the
job, they are out of date already,” he said.
|
|
|
|
|
5.5 ASCO
|
|
|
|
5.9 AACR
|
|
|
|
What the cancer 'moonshot' needs to fix [Politicio]
|
|
|
|
|
|
Simply
put, the amount of cancer-specific research being done in our country
does not track with the number of people who die from each cancer type.
More than ever before, there is a divide between two kinds of cancer:
those we can treat, leading to longer and better lives, and those that
rarely respond to treatment, despite our best efforts.
|
|
|
|
|
|
|
A Shared Commitment to the Cancer Moonshot [National Cancer Institute]
|
|
|
|
|
|
While
the Vice President applauded the dedication and notable achievements of
the cancer research community several times, he also challenged the
community to tell him how he can help to make it easier for
investigators to pursue their proposed research, how to accelerate
progress, and what bottlenecks, such as bureaucratic delays, might be
overcome through his efforts.
|
|
|
|
|
|
|
|
|
|
5.9.1 AACR - sein
|
|
|
|
5.9.5 AACR - T-cell immunothérapies
|
|
|
|
5.9.7 AACR - divers
|
|
|
|
|
5.9.9 AACR - immunothérapies
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
6.9 Controverses
|
|
|
NIH suspends clinical trials after contamination risk discovered [Nature News & Comment]
|
|
|
|
|
|
Oncologist
Steven Rosenberg’s lab at the National Cancer Institute (NCI) in
Bethesda, Maryland, is one of the two affected facilities. Rosenberg is
developing cancer therapies using immune cells called T lymphocytes,
which he engineers to attack a specific patient's cancer. After
discovering problems with Rosenberg’s cell-manufacturing lab, the NCI
suspended thirteen trials that used materials from the facility.
|
|
|
|
|
|